BNTC · CIK 1808898
What Benitec Biopharma Inc. told the SEC could break it.
Benitec's disclosures are those of a pre-revenue developer concentrated in one place and dependent on others. It has no approved products and no product sales, so it relies on raising capital — it held $97.7 million in cash at June 30, 2025 — to keep funding clinical development. All of its laboratory operations sit at a single facility in Hayward, California, where an earthquake, fire or other disaster could seriously compromise its ability to advance its product candidates. And because it intends to rely on third-party manufacturers to produce clinical and commercial quantities of those candidates, it faces the risk of being unable to secure such manufacturing agreements on reasonable terms.
3 self-disclosed vulnerabilities, pulled from its own filings, each in the company’s words, with the source. This is the risk register almost nobody reads.
In its own words
What could break it.
Climate & physical
- Single-location laboratory in Hayward, California (earthquake/disaster)medium
All laboratory operations are concentrated at a single Hayward, California facility; an earthquake, fire, flood, or other disaster there could seriously compromise the company's ability to operate and advance its product candidates.
“Our current laboratory operations are located in our facility situated in Hayward, California. Any unplanned event, such as flood, fire, explosion, earthquake, extreme weather condition, medical epidemics and pandemics, power shortage, telecommunication failure or other natural or manmade accidents or incidents”
SEC filing →As of 2025
Liquidity & debt
- Pre-revenue capital dependencemedium
Benitec has no approved products and no product revenue and depends on raising capital (it had $97.7M cash at June 30, 2025) to fund continued clinical development.
“We do not have any products approved for sale and have not generated any revenue from product sales. We do not know when, or if, we will generate any revenue from product sales.”
SEC filing →As of 2025
Supplier concentration
- Reliance on third-party manufacturers (CMOs) for product candidatesmedium
Benitec intends to rely on third-party manufacturers to produce clinical and commercial quantities of its product candidates and may be unable to negotiate such agreements on reasonable terms, creating manufacturing-supply risk.
“We intend to rely on third-party manufacturers for commercialization and production of commercial quantities of our product candidates. We may be unable to negotiate agreements with third-party manufacturers to support our commercialization activities on commercially reasonable terms.”
SEC filing →As of 2025
In the MyPRIA app, this is checked against the companies you actually own.
← World Watch